Cargando…

Public perceptions of the FDA’s marketing authorization of Vuse on Twitter/X

INTRODUCTION: On October 12, 2021, the FDA issued its first marketing granted orders for Vuse, the e-cigarette product by R.J. Reynolds Vapor Company. The public perceptions and reactions to the FDA’s Vuse authorization are prevalent on social media platforms such as Twitter/X. We aim to understand...

Descripción completa

Detalles Bibliográficos
Autores principales: Lee, Sarah, Xie, Zidian, Xu, Emily, Shao, Yihan, Ossip, Deborah J., Li, Dongmei
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Frontiers Media S.A. 2023
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10654997/
https://www.ncbi.nlm.nih.gov/pubmed/38026290
http://dx.doi.org/10.3389/fpubh.2023.1280658
_version_ 1785136731017707520
author Lee, Sarah
Xie, Zidian
Xu, Emily
Shao, Yihan
Ossip, Deborah J.
Li, Dongmei
author_facet Lee, Sarah
Xie, Zidian
Xu, Emily
Shao, Yihan
Ossip, Deborah J.
Li, Dongmei
author_sort Lee, Sarah
collection PubMed
description INTRODUCTION: On October 12, 2021, the FDA issued its first marketing granted orders for Vuse, the e-cigarette product by R.J. Reynolds Vapor Company. The public perceptions and reactions to the FDA’s Vuse authorization are prevalent on social media platforms such as Twitter/X. We aim to understand public perceptions of the FDA’s Vuse authorization in the US using Twitter/X data. METHODS: Through the Twitter/X streaming API (Application Programming Interface), 3,852 tweets between October 12, 2021, and October 23, 2021, were downloaded using the keyword of Vuse. With the elimination of retweets, irrelevant tweets, and tweets from other countries, the final dataset consisted of 523 relevant tweets from the US. Based on their attitudes toward the FDA authorization on Vuse, these tweets were coded into three major categories: positive, negative, and neutral. These tweets were further manually classified into different categories based on their contents. RESULTS: There was a large peak on Twitter/X mentioning FDA’s Vuse authorization on October 13, 2021, just after the authorization was announced. Of the 523 US tweets related to FDA’s Vuse authorization, 6.12% (n=32) were positive, 26.77% (n=140) were negative, and 67.11% (n=351) were neutral. In positive tweets, the dominant subcategory was Cessation Claims (n=18, 56.25%). In negative tweets, the topics Health Risk (n=43, 30.71%), Criticize Authorization (n=42, 30.00%), and Big Tobacco (n=40, 38.57%) were the major topics. News (n=271, 77.21%) was the most prevalent topic among neutral tweets. In addition, tweets with a positive attitude tend to have more likes. DISCUSSION: Public perceptions and discussions on Twitter/X regarding the FDA’s Vuse authorization in the US showed that Twitter/X users were more likely to show a negative than a positive attitude with a major concern about health risks.
format Online
Article
Text
id pubmed-10654997
institution National Center for Biotechnology Information
language English
publishDate 2023
publisher Frontiers Media S.A.
record_format MEDLINE/PubMed
spelling pubmed-106549972023-11-03 Public perceptions of the FDA’s marketing authorization of Vuse on Twitter/X Lee, Sarah Xie, Zidian Xu, Emily Shao, Yihan Ossip, Deborah J. Li, Dongmei Front Public Health Public Health INTRODUCTION: On October 12, 2021, the FDA issued its first marketing granted orders for Vuse, the e-cigarette product by R.J. Reynolds Vapor Company. The public perceptions and reactions to the FDA’s Vuse authorization are prevalent on social media platforms such as Twitter/X. We aim to understand public perceptions of the FDA’s Vuse authorization in the US using Twitter/X data. METHODS: Through the Twitter/X streaming API (Application Programming Interface), 3,852 tweets between October 12, 2021, and October 23, 2021, were downloaded using the keyword of Vuse. With the elimination of retweets, irrelevant tweets, and tweets from other countries, the final dataset consisted of 523 relevant tweets from the US. Based on their attitudes toward the FDA authorization on Vuse, these tweets were coded into three major categories: positive, negative, and neutral. These tweets were further manually classified into different categories based on their contents. RESULTS: There was a large peak on Twitter/X mentioning FDA’s Vuse authorization on October 13, 2021, just after the authorization was announced. Of the 523 US tweets related to FDA’s Vuse authorization, 6.12% (n=32) were positive, 26.77% (n=140) were negative, and 67.11% (n=351) were neutral. In positive tweets, the dominant subcategory was Cessation Claims (n=18, 56.25%). In negative tweets, the topics Health Risk (n=43, 30.71%), Criticize Authorization (n=42, 30.00%), and Big Tobacco (n=40, 38.57%) were the major topics. News (n=271, 77.21%) was the most prevalent topic among neutral tweets. In addition, tweets with a positive attitude tend to have more likes. DISCUSSION: Public perceptions and discussions on Twitter/X regarding the FDA’s Vuse authorization in the US showed that Twitter/X users were more likely to show a negative than a positive attitude with a major concern about health risks. Frontiers Media S.A. 2023-11-03 /pmc/articles/PMC10654997/ /pubmed/38026290 http://dx.doi.org/10.3389/fpubh.2023.1280658 Text en Copyright © 2023 Lee, Xie, Xu, Shao, Ossip and Li. https://creativecommons.org/licenses/by/4.0/This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.
spellingShingle Public Health
Lee, Sarah
Xie, Zidian
Xu, Emily
Shao, Yihan
Ossip, Deborah J.
Li, Dongmei
Public perceptions of the FDA’s marketing authorization of Vuse on Twitter/X
title Public perceptions of the FDA’s marketing authorization of Vuse on Twitter/X
title_full Public perceptions of the FDA’s marketing authorization of Vuse on Twitter/X
title_fullStr Public perceptions of the FDA’s marketing authorization of Vuse on Twitter/X
title_full_unstemmed Public perceptions of the FDA’s marketing authorization of Vuse on Twitter/X
title_short Public perceptions of the FDA’s marketing authorization of Vuse on Twitter/X
title_sort public perceptions of the fda’s marketing authorization of vuse on twitter/x
topic Public Health
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10654997/
https://www.ncbi.nlm.nih.gov/pubmed/38026290
http://dx.doi.org/10.3389/fpubh.2023.1280658
work_keys_str_mv AT leesarah publicperceptionsofthefdasmarketingauthorizationofvuseontwitterx
AT xiezidian publicperceptionsofthefdasmarketingauthorizationofvuseontwitterx
AT xuemily publicperceptionsofthefdasmarketingauthorizationofvuseontwitterx
AT shaoyihan publicperceptionsofthefdasmarketingauthorizationofvuseontwitterx
AT ossipdeborahj publicperceptionsofthefdasmarketingauthorizationofvuseontwitterx
AT lidongmei publicperceptionsofthefdasmarketingauthorizationofvuseontwitterx